

Record of Telephone Conversation, December 16, 2009 - Flublok

- Submission Type: BLA Submission ID: 125285/0 Office: OVRP
 Product:
 Influenza Vaccine
 Applicant:
 Protein Sciences Corporation
 Telecon Date/Time: 16-Dec-2009 08:36 AM Initiated by FDA? Yes
 Telephone Number:
 Communication Category(ies):
 1. Information Request

Author: TIMOTHY FRITZ
 Telecon Summary:
 Clarification of disposition for Study PSC04.
 FDA Participants: Timothy Fritz
 Non-FDA Participants: Penny Post
 Trans-BLA Group: No
 Related STNs: None
 Related PMCs: None
 Telecon Body:
 Dr. Post-

Our review of Protein Sciences Corporation FluBlok BLA 125285 is ongoing. We have the following request for clarification:

- Please clarify your disposition of subjects at Day 28 and Day 180.

From the Interim Study Report (ISR), original BLA Module 5, Volume 19, pp 52-54, Table 4 p 53 and Table 14.1.1 p 105, and the corresponding electronic datasets, the disposition of subjects at Day 28 appears to be as presented in Table 1:

Table 1: Subject Disposition through Day 28 Contact – ISR-PSC04

Disposition	Number of Subjects (%)		
	Treatment Group		
	Placebo n (%)	FluBlok n (%)	FluBlok Immunogenicity Subset n(%)
Randomized	2325 (100)	2323 (100)	391 (100)
Vaccinated*	2304 (100)	2344 (100)	391 (100)
Completed**	2211 (96%)	2249 (96%)	0

	Number of Subjects (%)		
Discontinued	93 (4%)	95 (4%)	0
Due to AE	0	0	
Lost to follow-up	85 (4%)	88 (4%)	
Withdrew consent	2 (<1)	7 (<1)	
Death	0	0	
Randomized, not Vaccinated	0	0	
Other reasons	6 (<1)	0	
Safety Population	2304	2344	
Evaluable Population (Immunogenicity)		391	391

In the Complete (Final) Study Report (CSR), Complete Response Module 5, Volume 2, pp 55-58, Table 4 p56 and Table 14.1.1 p 158, and corresponding electronic datasets, the disposition of subjects at Day 180 appears to be as presented in Table 2:

Table 2: CSR – Final Disposition of Subjects through Day 180 – PSC04

	#subjects(%)			
	Tx Gp			
Disposition	Placebo n (%)	FluBlok n (%)	Overall	FluBlok Immunogenicity Subset n(%)
Randomized	2325 (100)	2323 (100)	4648 (100)	480 (100)
Vaccinated*	2304 (100)	2344 (100)	4648 (100)	480 (100)
Completed**	2022 (88)	2049 (87)	4071 (88)	402 (84)
Discontinued	282 (12)	295 (13)	577 (12)	78 (16)
Due to AE	3 (<1)	3 (<1)	6 (<1)	0
Lost to follow-up	251 (11)	260 (11)	511 (11)	73 (15)
Withdrew consent	14 (1)	22 (1)	36 (1)	5 (1)
Death	1 (<1)	1 (<1)	2 (<1)	0
Randomized, not Vaccinated	0	0	0	0
Other reasons	13 (1)	9 (<1)	22 (<1)	0
Safety Population	2304	2344	4648	
Evaluable Population (Immunogenicity)		448		448

***Serology available for immunogenicity analysis post database lock

Although the CSR appears to present the data through the end of the study, the report states in Section 10.1, paragraph 1, p55, Mod 5 Vol 2, that “The disposition of the 4648 subjects enrolled in the study as of the **Day 28** contact is summarized in Table 4”, and then in paragraph 2, “No subjects died, and no subjects were discontinued due to AEs”. This latter sentence appears to refer to the Day 28 data, but paragraph 3 appears to describe subject disposition at the end of the study. Additionally, although Table 4, CSR p 56, Mod 5, Vol 2, is labeled “Subject Disposition through **Day 28** Contact”, the data appears to represent the end of study data (Day 180).

Please comment and provide a table(s) that presents the Disposition of Subjects at Day 28 versus Day 180. Please categorize discontinuations according to reason for discontinuation including:

- Due to AE
- Lost to follow-up
- Withdrew consent
- Death
- Randomized, not vaccinated
- Other

If you have any questions, please contact the Regulatory Project Managers, Katherine Matrakas or Timothy Fritz, at 301-827-3070.

Thank you.

Timothy A. Fritz, Ph.D.

Microbiologist

FDA/CBER/OVRR/DVRPA/RRB2

WOC1 HFM-478 Suite 371N

1401 Rockville Pike

Rockville, MD 20852

Phone: 301-827-3070

Fax: 301-827-1597

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.